Printer Friendly

COMPANY INFORMATION
Amorfix Life Sciences Ltd. 3403 American Dr Mississauga, ON L4V 1T4 Tel: (416) 847-6898 Fax: (416) 847-6899 Contact Name Vigen Nazarian Industry Biotechnology		Key Executives George Adams, CEO James Parsons, CFO Develops therapeutic products and diagnostic devices for diseases where aggregated misfolded proteins (AMP) are prevalent. These include transmissible spongiform encephalopathies (TSE), such as bovine spongiform encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as neurodegenerative diseases such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), and cancer.
FP ADVISOR COVERAGE Amorfix Life Sciences Ltd. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/AMF $0.50 $1.35 $0.42 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 66,316 n.a. $-0.10 Sept. 30/09 -46.81% -28.71% n.a. $24,204
ANNUAL FINANCIALS Periods ended: 12m Mar. 31/09 12m Mar. 31/08 12m Mar. 31/07 $000s $000s $000s Net income (5,148) (7,190) (4,234) Total assets 5,517 9,990 14,734 $ $ $ Earnings per share* (0.12) (0.17) (0.13) % % % Return on equity (75.62) (63.16) (43.72)   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 $000s $000s Net income (4,852) (6,151) $ $ Earnings per share (0.11) (0.15)

COMPANY NEWS

Results for 'Amorfix Life Sciences Ltd.' from past 30 days: No hits. (Links are to articles.)